• +1-646-491-9876
    • +91-20-67278686

    Search

    5-Hydroxytryptamine Receptor 7 Pipeline Review H1 2017

    5-Hydroxytryptamine Receptor 7 Pipeline Review H1 2017

    • Report Code ID: RW0001858692
    • Category Pharmaceuticals
    • No. of Pages 65
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H1 2017

    Summary

    5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - 5-HT7 receptor is a member of the GPCR superfamily and it is activated by the serotonin (5-HT) . The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It plays an important role in autistic disorder and other neuropsychiatric disorders.

    5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 1 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal and Genetic Disorders which include indications Psychiatric Disorders, Bipolar Disorder (Manic Depression) , Schizophrenia, Attention Deficit Hyperactivity Disorder (ADHD) , Autism, Major Depressive Disorder, Anxiety Disorders, Cognitive Disorders, Fragile X Syndrome, Inflammatory Pain, Irritable Bowel Syndrome, Migraine, Neuropathic Pain, Pervasive Developmental Disorder (PDD) , Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder, Social Anxiety Disorders (SAD) and Tourette Syndrome.

    The latest report 5-Hydroxytryptamine Receptor 7 - Pipeline Review, H1 2017, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
    - The report reviews 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics and enlists all their major and minor projects
    - The report assesses 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Overview
    5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Companies Involved in Therapeutics Development
    Adamed Sp z oo
    Astellas Pharma Inc
    Braeburn Pharmaceuticals Inc
    H. Lundbeck A/S
    Johnson & Johnson
    Reviva Pharmaceuticals Inc
    Sumitomo Dainippon Pharma Co Ltd
    5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Drug Profiles
    ADN-1184 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ADN-3662 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ATI-9242 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DDD-028 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JNJ-18038683 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lurasidone hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RP-5063 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SERx-519 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Agonize Alpha 2 Adrenergic Receptor and Antagonize 5-HT7 and 5-HT5A Receptors for Psychiatric Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    vortioxetine hydrobromide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Dormant Products
    5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Discontinued Products
    5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Product Development Milestones
    Featured News & Press Releases
    Jun 09, 2017: Sumitomo Dainippon Pharma Announces Topline Results from a Phase 3 Study of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Bipolar l Depression
    May 22, 2017: Sunovion Announces Positive Results from Study Evaluating Latuda (lurasidone HCl) in Children and Adolescents with Bipolar Depression at Annual American Psychiatric Association Meeting
    May 16, 2017: Sunovion to Present Data on Latuda (lurasidone HCl) at Annual American Psychiatric Association Meeting
    Mar 31, 2017: Sunovion to Present Data on LATUDA (lurasidone HCI) at the 25th European Congress of Psychiatry
    Feb 27, 2017: Sunovion Announces Positive Topline Results from Study Evaluating Latuda (lurasidone HCl) in Children and Adolescents with Bipolar Depression
    Jan 28, 2017: Sunovion's Latuda (lurasidone HCl) Receives FDA Approval to Treat Adolescents with Schizophrenia
    Dec 02, 2016: Sunovion to Present Data on Latuda (lurasidone HCl) at the 55th Annual Meeting of the American College of Neuropsychopharmacology
    Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)
    Oct 27, 2016: Sunovion Announces Positive Clinical Study Results for Latuda (lurasidone HCl) in Adolescents with Schizophrenia
    Sep 16, 2016: Sunovion to Present Data on Latuda (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress
    Aug 08, 2016: Sunovion Announces Publication of Data Evaluating Dose Escalation of Latuda (lurasidone HCl) in the Treatment of Schizophrenia
    Jun 02, 2016: Trintellix (vortioxetine) Now Available in U.S. Pharmacies
    May 23, 2016: Sunovion Announces Publication of Data Evaluating the Long-Term Safety and Tolerability of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression
    May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016
    May 16, 2016: Takeda and Lundbeck Present Vortioxetine Data at the American Psychiatric Association 2016 Annual Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Adamed Sp z oo, H1 2017
    Pipeline by Astellas Pharma Inc, H1 2017
    Pipeline by Braeburn Pharmaceuticals Inc, H1 2017
    Pipeline by H. Lundbeck A/S, H1 2017
    Pipeline by Johnson & Johnson, H1 2017
    Pipeline by Reviva Pharmaceuticals Inc, H1 2017
    Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
    Dormant Projects, H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Type,, H1 2017
    Adamed Sp z oo
    Astellas Pharma Inc
    Braeburn Pharmaceuticals Inc
    H. Lundbeck A/S
    Johnson & Johnson
    Reviva Pharmaceuticals Inc
    Sumitomo Dainippon Pharma Co Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//5-hydroxytryptamine-receptor-7-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//5-hydroxytryptamine-receptor-7-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//5-hydroxytryptamine-receptor-7-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments